Coherus Oncology to Share Interim Tagmokitug Clinical Data on October 28
Coherus Oncology, Inc. (NASDAQ:CHRS) plans to release interim clinical data for its tagmokitug development program on Wednesday, October 28, 2026. Executive management will host a live webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to review the results, joined by key opinion leaders who will provide expert clinical context.
Tagmokitug is an experimental cytolytic CCR8 antibody currently undergoing Phase 1b/2a clinical trial testing in combination with toripalimab, the company's approved PD-1 inhibitor marketed as LOQTORZI. The drug candidate is being studied as a potential treatment for multiple advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancers.
Investors and healthcare researchers can follow the presentation via a webcast hosted on the company's investor relations website, where accompanying presentation materials will be posted after the event. Stock in Coherus Oncology was trading at $1.05 per share following the announcement.
Key points
- Coherus Oncology will release interim clinical data for its experimental drug tagmokitug on October 28, 2026.
- Tagmokitug is a selective cytolytic anti-CCR8 antibody in Phase 1b/2a trials for advanced solid tumors.
- The study evaluates tagmokitug combined with toripalimab, an approved PD-1 inhibitor marketed as LOQTORZI.
- Company management will host a webcast from 4:30 p.m. to 6:00 p.m. EDT with clinical insights from key opinion leaders.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When will Coherus Oncology release the interim tagmokitug clinical data?
Coherus Oncology will share the interim data on Wednesday, October 28, 2026, during a webcast scheduled from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time.
What is tagmokitug and how is it being tested?
Tagmokitug is an experimental cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies, evaluated alongside toripalimab in patients with various advanced solid tumors.
How can investors access the Coherus Oncology webcast?
Investors can pre-register for dial-in access or listen to the live and archived webcast on the Investor Relations section of the Coherus Oncology website.